About Ovumia Group
Established in 2007, Ovumia initially focused on IVF laboratory services and expanded to full-scale fertility treatments in 2011. By 2015, Ovumia had extended its reach to Estonia and acquired four additional clinics in Finland between 2015 and 2022. In 2019, FutureLife from the Czech Republic became a strategic partner, fostering joint R&D and knowledge exchange.
Ovumia continued its growth by acquiring Urogyn in Stockholm, Sweden, and Alternatyva in Lviv, Ukraine, in 2023. Today, Ovumia Group employs around 250 top professionals, delivering specialist medical services and high-quality laboratory work.
Ovumia handles over 70% of all egg donor treatments in Finland, coordinates the Ovumia Group Egg and Sperm Banks, and serves as a center of excellence for molecular reproductive biology and DNA diagnostics in Finland. Leading the way in developing fertility treatment services and technologies, Ovumia’s success is driven by continuous R&D, ensuring that its offerings—including fertility investigations, embryo diagnostics, ultrasound examinations, and gynecological services—are the most advanced in the field.
